Research Insight
Teva announced new data from the Phase III placebo-controlled and randomized First Time Use of SD-809 in HuntingtonDisease
Teva Pharmaceutical Industries Ltd., announced new data from the Phase III placebo-controlled and randomized First Time Use of SD-809 in HuntingtonDisease (First-HD) study evaluating the efficacy, safety and tolerability of SD-809 (deutetrabenazine) for the treatment of chorea associated with...
Research Insight
IMS Health Study: U.S. Drug Spending Growth Reaches 8.5 Percent in 2015
Total spending on medicines in the U.S. reached $310 billion in 2015 on an estimated net price basis, up 8.5 percent from the previous year, according to a new report issued today by the IMS Institute for Healthcare Informatics....
Research Insight
Amgen, UCB Present reports on comparing Romosozumab With Teriparatide
In Phase 3 Open-Label STRUCTURE Study Postmenopausal Women With Osteoporosis Transitioning From Oral Bisphosphonates to Romosozumab Experienced Consistent and Significant Gains in Bone Mass and Estimated Strength Over Teriparatide. World pharma today/Research inside/-Amgen and UCB announced detailed Phase 3...
Research Insight
The diabetes drug pioglitazone is associated with an increased risk of bladder cancer
The diabetes drug pioglitazone is associated with an increased risk of bladder cancer, finds a study published by The BMJ today. The findings suggest that the risk increases with increasing duration of use and dose. Pioglitazone...
Research Insight
Penn Study Describes the Molecular Cause of Common Cerebrovascular Disease
Cerebral cavernous malformations (CCMs) are clusters of dilated, thin-walled blood vessels in the brain that can cause stroke and seizures, yet exactly how they form is somewhat of a mystery. Now, a team from the Perelman School of Medicine...
Research Insight
FDA approves new indication for Novartis drug Afinitor
Novartis announced that the United States Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced...
Research Insight
Studies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company announced that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that evaluated the effect of ixekizumab on work productivity in patients with moderate-to-severe plaque psoriasis. Specific results from the UNCOVER-1 study...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read